Skip to content

A Trial of Corticosteroids for Low Back Pain

Utility of Intramuscular Corticosteroids for Radicular Low Back Pain

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00290589
Enrollment
82
Registered
2006-02-13
Start date
2003-06-30
Completion date
2007-08-31
Last updated
2019-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radicular Low Back Pain

Keywords

low back pain, emergency department, corticosteroids

Brief summary

Low back pain is a common symptom that functionally disables many people. When the low back pain is accompanied by pain that shoots down the leg, it is felt to be caused by a herniated disc. We are conducting this study to determine if a powerful anti-inflammatory agent will decrease the pain and functional impairment that is associated with this illness.

Detailed description

This is a randomized, double-blind placebo-controlled clinical trial evaluating intramuscular methylprednisolone acetate as adjunctive therapy for radicular low back pain. This trial randomizes subjects after they had been evaluated and treated in the ED and are ready for discharge. All subjects are followed by telephone call one week and one month after ED discharge. In addition to the steroid injection, all subjects are given a complimentary one week supply of naproxen 500 mg tablets and oxycodone 5mg/ acetaminophen 325 tablets and a detailed low back pain instruction sheet. This study was approved by the Montefiore Medical Center institutional review board. Patients are included if their low back pain lasted less than one week, if they are 50 years old or younger, and if they had not experienced any direct trauma to the back during the previous week. Low back pain is described as pain originating below the tips of the scapulae and above the buttocks.Patients are only included if their straight leg raise test, as described below, is positive. Patients are excluded if the emergency physician felt that there is a high likelihood that the patient has a secondary cause of low back pain, e.g., metastatic bone disease or infection. Patients are also excluded for temperature greater than 100.3 degrees, pregnancy, lactation, allergy to or intolerance of a study medication. Patients can only enroll once. Patients can not have had another episode of back pain within four weeks prior to the current back pain attack. Patients are excluded for systemic steroid use within four weeks, a history of back surgery, a neoplasia known to metastasize, a chronic pain syndrome, an inflammatory arthritis, suspected vascular, urologic or gynecologic pathology, or direct blunt trauma to the back within the previous week. Rationale for the straight leg raise test: Although the true test characteristics of the straight leg raise test are unknown, a positive ipsilateral straight leg raise is felt to be a sensitive marker for a herniated intervertebral disc. Therefore, if this test is negative, it can help rule-out the disease. To maintain a homogenous cohort, subjects were stratified based on results of the straight leg raise test. Many definitions of the straight leg raise test exist. In order to identify distinct populations, the research assistants were given a strictly-defined, conservative definition of this test: namely, the test was considered positive if a subject had ipsilateral pain shooting below the knee when either leg was raised between 30 and 70 degrees, as measured with a protractor. Contralateral pain below the knee, considered more specific for a herniated disc, was also considered a positive straight leg raising test. All patients with low back pain are treated at the discretion of the attending physician. When the patient's pain had been controlled to a level sufficient for the patient to be discharged, the patient is asked for consent to participate as a research subject. After consent is obtained, subjects receive an intramuscular injection of methylprednisolone acetate or placebo. All subjects are discharged with a back pack containing 14 tablets of naproxen 500mg, 12 tablets of oxycodone 5mg/ acetaminophen 325 tablets, and a standardized discharge instruction sheet. Subjects are followed-up by telephone at one week and one month after discharge. At each of these telephone interviews, research assistants read standardized questions about pain and activity limitations from the data collection instrument.

Interventions

DRUGIntramuscular methylprednisolone acetate

Intramuscular methylprednisolone acetate 160mg

DRUGPlacebo

Normal saline intramuscular injection

Sponsors

Montefiore Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* 21-50 years old, non-traumatic low back pain for one week or less,

Exclusion criteria

* fever, pregnancy, lactation, allergy or intolerance to study medication, suspected active oncologic, urologic, or gynecologic disease

Design outcomes

Primary

MeasureTime frameDescription
Numerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable1 monthImprovement in Numerical Rating Scale between the time of the emergency department visit and the one month telephone call is rated on an 11-point scale ranging from 0-10 with 0 indicating no pain and 10 indicating worse pain imaginable.
Functional Disability Scales1 monthThe low back pain functional disability scale is the Roland Morris Disability questionnaire score (RMDQ). The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment.

Secondary

MeasureTime frameDescription
Number of Patients Using AnalgesicsAssessed at 1 monthUse of analgesics for low back pain (within the previous 24 hours)

Countries

United States

Participant flow

Participants by arm

ArmCount
Intramuscular Methylprednisolone Acetate
Methylprednisolone acetate 160mg intramuscular injection intramuscular methylprednisolone acetate: Intramuscular methylprednisolone acetate 160mg
39
Placebo
Placebo intramuscular injection Placebo: Normal saline intramuscular injection
43
Total82

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up22

Baseline characteristics

CharacteristicIntramuscular Methylprednisolone AcetatePlaceboTotal
Age, Continuous39 Years
STANDARD_DEVIATION 9
37 Years
STANDARD_DEVIATION 8
38 Years
STANDARD_DEVIATION 9
Duration of Back Pain Prior to Study48 hours48 hours48 hours
Region of Enrollment
United States
39 Participants43 Participants82 Participants
Sex: Female, Male
Female
21 Participants22 Participants43 Participants
Sex: Female, Male
Male
18 Participants21 Participants39 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 370 / 41
other
Total, other adverse events
12 / 3710 / 43
serious
Total, serious adverse events
0 / 370 / 41

Outcome results

Primary

Functional Disability Scales

The low back pain functional disability scale is the Roland Morris Disability questionnaire score (RMDQ). The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment.

Time frame: 1 month

ArmMeasureValue (MEDIAN)
Intramuscular Methylprednisolone AcetateFunctional Disability Scales0 units on a scale
PlaceboFunctional Disability Scales0 units on a scale
Primary

Numerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable

Improvement in Numerical Rating Scale between the time of the emergency department visit and the one month telephone call is rated on an 11-point scale ranging from 0-10 with 0 indicating no pain and 10 indicating worse pain imaginable.

Time frame: 1 month

ArmMeasureValue (MEAN)Dispersion
Intramuscular Methylprednisolone AcetateNumerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable7.1 units on a scaleStandard Deviation 3
PlaceboNumerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable5.8 units on a scaleStandard Deviation 3.5
Secondary

Number of Patients Using Analgesics

Use of analgesics for low back pain (within the previous 24 hours)

Time frame: Assessed at 1 month

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intramuscular Methylprednisolone AcetateNumber of Patients Using Analgesics8 Participants
PlaceboNumber of Patients Using Analgesics17 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026